Human cathelicidin ll 37

Human cathelicidin LL-37 (AnaSpec, Fremont, CA, USA); porcine protegrin-1 (PG-1), (SynPep, Dublin, CA, USA); 7S of nerve growth factor from murine submaxillary gland (Sigma-Aldrich, Darmstadt, Germany); gentamicin sulfate (solution for intravenous and intramuscular administration, 40 mg/mL, Shandong Weifang Pharmaceutical Factory Co., Liaocheng, China); temozolomide (Temodal capsules, 100 mg, Orion Corporation, Orion Pharma, Espoo, Finland); an XF Cell Mito Stress Test Kit and Glycolysis Stress Test kit were purchased from Seahorse Bioscience (USA).

Experiments involving histone treatments used calf thymus histone H2A (Sigma, St. Louis, MO), human histone H3 (Cayman Chemical, Ann Arbor, MI), or citrullinated human histone H3 (Cayman Chemical, Ann Arbor, MI). Experiments involving antimicrobial peptide treatment used the human cathelicidin LL-37 (Anaspec, Fremont, CA), FAM-LC-LL-37 (Anaspec, Fremont, CA), or magainin-2 (Anaspec, Fremont, CA). Experiments involving antibiotic treatments used kanamycin sulfate (Sigma), chloramphenicol (Sigma), or polymyxin B sulfate salt (Sigma).

Human cathelicidin LL-37 (AnaSpec, Fremont, CA, USA); porcine protegrin-1 (PG-1), (SynPep, Dublin, CA, USA); 7S of nerve growth factor from murine submaxillary gland (Sigma-Aldrich, Darmstadt, Germany); gentamicin sulfate (solution for intravenous and intramuscular administration, 40 mg/mL, Shandong Weifang Pharmaceutical Factory Co., Liaocheng, China); Doxorubicin-LANS^® (solution for intravascular and intravesical administration, 2 mg/mL, 5 mL, Veropharm, Moscow, Russia); Carboplatin-LANS^® (concentrate for the preparation of the solution for infusion, 10 mg/mL, 5 mL, Veropharm, Moscow, Russia); temozolomide (Temodal capsules, 100 mg, Orion Corporation, Orion Pharma, Espoo, Finland); Cisplatin-LANS^® (solution 0.5 mg/mL, 50 mL, Veropharm, Moscow, Russia); etoposide (Ebeve) (20 mg/mL, solution for infusion 10 mL, Ebewe Pharma, Unterach am Attersee, Austria).